68Ga-NI-FAPI PET/CT: First-in-human Study

Recruiting now · Early Phase 1

Conditions studied: Malignant Neoplasm

In brief

68Ga-NI-FAPI is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole (NI)-moiety and a FAP-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of 68Ga-NI-FAPI PET/CT in patients with different types of cancer.

Key facts

Study ID

NCT06688305

Run by

First Affiliated Hospital of Fujian Medical University

People needed

40

Starts

2024-08-01

Expected to finish

2025-12-31

Last updated by the study team

2024-11-14

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Various solid tumors with available histopathological findings
• Signed informed consent

You may not qualify if…

• pregnant or lactational women
• who suffered from severe hepatic and renal insufficiency

Where it is running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.